Triple-Drug attack aims to stop liver cancer recurrence after surgery
NCT ID NCT07682272
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This phase II trial investigates whether adding SHR-8068 to a two-drug regimen (adebrelimab and apatinib) can improve outcomes for people with liver cancer that can be surgically removed but has a moderate-to-high risk of coming back. Participants receive the drug combination before and after surgery. The main goal is to see if the treatment shrinks the tumor significantly before surgery, and researchers also track how long people stay cancer-free and any side effects.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- SHR-8068, adebrelimab, and apatinib
- What this could lead to
- If successful, this combination could reduce the chance of liver cancer returning after surgery, offering a new perioperative treatment option.
- What could go wrong
- This is an early-phase trial with a small number of participants. The combination may cause significant side effects, and it is not yet known if it will improve long-term outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 120 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jul 2026
An estimate. Start dates often move.
- Expected to finish
-
Jul 2029
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Subjects who voluntarily participate in this study and sign the informed consent form. 2. Age from 18 to 70, male or female. 3. Histopathologically/cytologically confirmed or clinically diagnosed with hepatocellular carcinoma (HCC). 4. At least one measurable lesion based on RECIST v1.1. 5. No prior systemic antitumor therapy for HCC. 6. ECOG Performance Status (PS) score of 0-1. 7. Child-Pugh liver function class A. 8. Expected survival at least 3 months. 9. Adequate organ function. 10. Blood pregnancy negative (women of childbearing age) and non-breastfeeding, effective contraception. Exclusion Criteria: 1. Known intrahepatic cholangiocarcinoma, sarcomatoid hepatocellular carcinoma, mixed hepatocellular carcinoma, or fibrolamellar hepatocellular carcinoma. 2. Other malignancies within the past 5 years or concurrent malignancy. 3. Known history of severe hypersensitivity reaction to any monoclonal antibody. 4. Previous or current central nervous system metastases. 5. Clinically symptomatic moderate or severe ascites requiring therapeutic paracentesis or drainage. 6. Hypertension that cannot be well controlled with antihypertensive medication. 7. Poorly controlled cardiac symptoms or heart disease. 8. Known hereditary or acquired bleeding disorders (e.g., coagulopathy) or thrombotic tendency. 9. Arterial thrombotic or embolic events within 6 months before enrollment. 10. Any other condition that, in the investigator's judgment, may affect the study results or lead to premature termination of the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Resectable hepatocellular carcinoma with intermediate or high recurrence risk are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Zhongshan Hospital Fudan University
Shanghai, Shanghai Municipality, 200032, China